Navigation Links
Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009
Date:4/30/2009

VANCOUVER, April 30 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today announced its financial results for the first quarter ended March 31, 2009.

"We were pleased to post solid results for our first quarter in what has been a difficult business environment for many companies," said Dr. William Hunter, President and CEO of Angiotech. "Sales in our proprietary Surgical and Interventional business areas continued to show very promising growth, with Quill SRS in particular garnering greater acceptance in new hospitals and surgical disciplines, and we continued to realize expense reductions as compared to the prior quarter. Additionally, our royalty revenue increased as compared to the fourth quarter of last year, indicating an improved market position for our partner Boston Scientific and higher sales of paclitaxel-eluting stents."

    First Quarter Financial Highlights

    -  Total revenue was $88.3 million. Total revenue was $63.2 million on
       an adjusted basis, excluding one-time license revenue of $25 million
       received from our partner Baxter International Inc. ("Baxter")
       relating to our amended and restated Distribution and License
       Agreement, as announced on March 31, 2009.

    -  Net product sales were $46.1 million.

    -  Royalty revenue was $17.1 million.

    -  Adjusted EBITDA (earnings before interest, taxes, depreciation and
       amortization, adjusted to exclude certain non-cash and non-recurring
       items) was $14.6 million.

    -  Research and development expenses were $6.1 million, and as adjusted
       to exclude non-cash stock-based compensation expenses and
       non-recurring termination related costs were $5.7 million. These
       results compare to $7.7 million and $6.9 million, respectively, in
       the fourth quarter of 
'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Related biology technology :

1. Angiotech announces date of annual general meeting of shareholders
2. Angiotech Pharmaceuticals, Inc. Announces Conference Call And Webcast
3. Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc.
4. Angiotech announces positive results from Bio-Seal(TM) clinical study
5. Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008
6. Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities
7. Angiotech Pharmaceuticals announces time change of conference call and webcast
8. Angiotech announces termination of note purchase agreement with Ares Management and New Leaf Venture Partners
9. Angiotech Announces Webcast and Call-in Numbers for Annual and Special General Meeting of Shareholders
10. Angiotech Announces Extension of the Expiration Date of its Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014
11. Angiotech receives CE Mark approval of HemoStream(TM) Chronic Dialysis Catheter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... More than 5 million Americans are ... 3 seniors will die with Alzheimer’s or another dementia, ... have shocked many Americans into looking for ways to ... tragic age-related cognitive disorders. Jonathan Weisman, president of Biohack ...
(Date:1/15/2014)... CA (PRWEB) January 15, 2014 ... research solutions, today announced that Lupin Limited, one of ... Freeslate’s CM Protégé PharmD System for high ... Mumbai, India, is focused on a wide range of ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Histogen, Inc., ... products of cells grown under simulated embryonic conditions, today ... agreement with Suneva Medical, Inc. for physician-dispensed aesthetic products ... , This agreement is an amendment to the ...
(Date:1/14/2014)... and BETHESDA, Md. , Jan. 14, ... with two institutes from the National Institutes of Health ... bringing safer, more effective treatments to patients on a ... for Advancing Translational Sciences (NCATS) and the National Eye ...
Breaking Biology Technology:Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3
... TORONTO, Sept. 6, 2011 Generex Biotechnology Corporation ( ... of the Company,s reorganization plan and following a comprehensive ... assessment, the Company has completed the sales of two ... proceeds of just over $1,000,000.  The tenanted properties were ...
... 2011 The Immune Deficiency Foundation (IDF) announced today ... (CE) course for  nurses. The goal of this CE ... providing an educational update on primary immunodeficiency disease and ... national patient organization dedicated to improving the diagnosis, treatment ...
... OXIS International, Inc. (OTC Bulletin Board: OXIS ... Saloff as Chief Executive Officer.  Mr. Saloff was appointed to ... "David,s proven ability to move companies from development stage ... OXIS at this time," said Anthony J. Cataldo, Chairman of ...
Cached Biology Technology:Generex Augments Cash Position With Sales of Non-Essential Assets 2Generex Augments Cash Position With Sales of Non-Essential Assets 3Immune Deficiency Foundation Launches Free Accredited Course for Nurses About Primary Immunodeficiency and Immunoglobulin Therapy 2Immune Deficiency Foundation Launches Free Accredited Course for Nurses About Primary Immunodeficiency and Immunoglobulin Therapy 3OXIS International Names David Saloff as Chief Executive Officer 2OXIS International Names David Saloff as Chief Executive Officer 3
(Date:4/17/2014)... consumption advisories for expecting mothers are ineffective in ... organic pollutants (POPs). , The study, performed ... Toronto Scarborough PhD student Matt Binnington and Professor ... environmental contamination, a mother,s compliance with advisories, and ... exposure in her children. , Their model estimates ...
(Date:4/17/2014)... German . ... also provide us with a continuous stream of information about ... sit still in a car the world glides by ... Seemingly without effort, our brain calculates self-motion from this "optic ... a steady gaze during our own movements. Together with biologists ...
(Date:4/17/2014)... House honored Clemson professor Rajendra Singh Thursday as ... promote and expand solar deployment in the residential, ... Houser Banks Professor of Electrical and Computer Engineering ... is considered a local hero leading the charge ... opportunity in solar power and driving policy changes ...
Breaking Biology News(10 mins):Fish consumption advisories fail to cover all types of contaminants 2How vision makes sure that little fish do not get carried away 2How vision makes sure that little fish do not get carried away 3How vision makes sure that little fish do not get carried away 4White House honors Clemson professor as 'Champion of Change' for solar deployment 2
... news media splash photos of the company,s CEO around the ... Research the shape of the CEO,s face evokes judgments about ... what face is put on the crisis, and [our] research ... a trivial consideration," say authors Gerald J. Gorn, Yuwei Jiang ...
... Medical Research, led by Jos Luis Milln, Ph.D., have ... replacement therapy to prevent hypophosphatasia (HPP), a primary skeletal ... foundation for future clinical trials for HPP patients. ... that most commonly results from a lack of vitamin ...
... direct communication links between the human brain and ... themselves to changing environmental conditions, or computer chips ... medical technologies that eliminate currently untreatable conditions such ... these developments occurring at the same time. Far-fetched? ...
Cached Biology News:Potential therapy discovered for hypophosphatasia, a congenital form of rickets 2The coming convergence 2The coming convergence 3
... mutS are mismatch repair minus strains of ... repair of the newly synthesized unmethylated strand ... making them helpful in such systems as ... Systems. Both ES1301 and BMH 71-18 mutS ...
1 unit is sufficient for 1 caspase activity assay....
RABBIT ANTI WARFARIN...
Request Info...
Biology Products: